Valuation: Opus Genetics, Inc.

Market Cap 304M 262M 247M 224M 422M 29.1B 428M 2.89B 1.13B 14.55B 1.14B 1.12B 48.47B P/E 2026 *
-3.69x
P/E 2027 * -5.18x
Enterprise Value 304M 262M 247M 224M 422M 29.1B 428M 2.89B 1.13B 14.55B 1.14B 1.12B 48.47B EV / Sales 2026 *
22.6x
EV / Sales 2027 * 21.1x
Free-Float
89.06%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Opus Genetics, Inc.

1 day+1.10%
1 week+0.82%
Current month-0.54%
1 month+12.84%
3 months-23.12%
6 months-5.14%
Current year+83.58%
1 week 3.55
Extreme 3.55
3.99
1 month 2.82
Extreme 2.82
3.99
Current year 1.88
Extreme 1.88
5.81
1 year 1.1
Extreme 1.1
5.81
3 years 0.65
Extreme 0.65
5.81
5 years 0.65
Extreme 0.65
6.6
10 years 0.65
Extreme 0.65
13.81
Manager TitleAgeSince
Chief Executive Officer 42 31/10/2023
Director of Finance/CFO 52 01/09/2025
President 60 21/10/2024
Director TitleAgeSince
Director/Board Member 77 31/10/2020
Chairman 56 30/11/2019
Director/Board Member 59 31/10/2020
Date Insider Type Main position Quantity % Market Cap.
23/07/26 Sell

Chief Financial Officer

-7,783 0.0094%
23/07/26 Sell

Chairperson

-7,429 0.0090%
23/07/26 Sell

Chief Executive Officer

-9,475 0.0115%
Change 5-day change 1-year change 3-year change Capi.($)
+1.10%+0.82%+207.50%-9.56% 304M
+3.60%-0.50%+74.80%+127.97% 1,055B
+3.33%+3.55%+53.48%+55.80% 632B
+3.43%+4.42%+25.27%+72.59% 442B
+1.35%-3.27%+40.98%+39.91% 351B
+1.75%-0.98%+26.20%+39.73% 290B
+2.13%-1.53%+1.85%+9.40% 243B
+1.41%+1.94%+43.45%+61.18% 227B
+1.35%-3.20%-9.07%-53.51% 200B
+3.25%+7.80%+21.18%+87.50% 172B
Average +2.24%-1.32%+48.56%+43.10% 361.28B
Weighted average by Cap. +2.80%-1.87%+43.75%+68.75%

Financials

2026 *2027 *
Net sales 13.44M 11.6M 10.92M 9.92M 18.66M 1.29B 18.94M 128M 50.19M 644M 50.44M 49.35M 2.14B 14.39M 12.43M 11.7M 10.63M 19.99M 1.38B 20.29M 137M 53.77M 690M 54.04M 52.87M 2.3B
Net income -92.68M -80.05M -75.31M -68.45M -129M -8.88B -131M -883M -346M -4.44B -348M -340M -14.79B -68.16M -58.87M -55.39M -50.34M -94.69M -6.53B -96.08M -650M -255M -3.27B -256M -250M -10.88B
Net Debt - -
Logo Opus Genetics, Inc.
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
Employees
28
Date Price Change Volume
18/08/26 US$3.690 +1.10% 752,869
17/08/26 US$3.650 +1.11% 608,374
14/08/26 US$3.610 -2.96% 414,480
13/08/26 US$3.720 -1.06% 513,353
12/08/26 US$3.760 -3.09% 480,422
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
3.650USD
Average target price
10.61USD
Spread / Average Target
+190.72%

Quarterly revenue - Rate of surprise